Objective
Imagine a simple, affordable DNA test that can flag who is most likely to develop T1D years before any symptoms appear. That is the heart of this project. Our overarching goal is to design a **Genetic Risk Score (GRS) made especially for East Asian people**—a population that includes more than 1.7 billion individuals across Japan, China, Korea, Taiwan, and many other countries.
Why do we need a new test?
Today’s best-known T1D GRS was built almost entirely from European genetic data. When that score is used in East Asian families, it often misses those truly at risk and sometimes labels low-risk people as high-risk. In practical terms, that means many East Asian children and adults remain invisible to early-detection programs and cannot benefit from timely monitoring or new preventive medicines such as teplizumab. Our objective is to close this equity gap with a score tuned to East Asian DNA.
What exactly will we do?
Over the next two years we will gather saliva samples from 2,000 volunteers—half with T1D and half with type 2 diabetes—from ten endocrinology clinics across Japan. A certified Japanese laboratory will scan each sample for hundreds of thousands of genetic markers. Using advanced computer models, we will discover which combinations of markers truly distinguish T1D from type 2 diabetes in East Asians. Those markers and their weights will become the East-Asian Genetic Risk Score.
How is privacy protected?
All DNA files will be coded so no one outside the clinic can see names or personal details. Files will move through encrypted channels to a secure cloud, be analyzed for a few months, then permanently deleted. The original samples never leave Japan.
What happens after the score is built?
We have a two-step plan. First, we will share the score openly with scientists, doctors, and patient groups, so any hospital or university can test it on their own East Asian patients. Second, we will work with our clinical partners to offer the score as a low-cost add-on to routine blood or health-check DNA panels. That way, families can learn their genetic risk early, enroll in follow-up antibody screening, and—if needed—receive teplizumab or other new therapies before serious damage occurs.
Long-term vision.
Once validated, the score can be used for the first population-wide T1D genetic screening service in Asia. A similar approach could then be adapted for South Asian, African, or Latin American communities, helping to ensure that one’s ancestry no longer dictates access to life-saving early detection.
In short, our objective is clear and measurable: deliver a genetic test that accurately spots East Asian people at high risk for type 1 diabetes, and make that test easy to use in everyday clinics. By doing so, we lay the foundation for fairer, faster, and more effective prevention of T1D across a huge part of the world.
Background Rationale
Type 1 diabetes begins when the immune system mistakenly attacks the insulin-producing cells in the pancreas. For months or even years before symptoms, a person enters a “silent” phase during which blood sugar may be normal, yet the destruction has already started. Identifying people in this silent phase is crucial because:
1. It saves lives.
Up to 60 percent of children who are diagnosed unexpectedly arrive in hospital with diabetic ketoacidosis, a life-threatening emergency. Early detection slashes that risk.
2. It opens the door to preventive treatment.
In 2022 the U.S. Food and Drug Administration approved teplizumab, the first medicine shown to delay the onset of T1D. But the drug only works if you know who is at high risk.
3. It accelerates research.
Clinical trials for new therapies struggle to recruit participants in the “silent” phase, especially among non-European groups.
Genetic Risk Scores (GRS) are the most practical first screen. A GRS is a single number calculated from a few dozen DNA markers. If the score is high, doctors can offer regular antibody checks; if antibodies appear, further tests confirm the risk and preventive treatment can begin. Because DNA never changes, the test can be done once at birth, during childhood, or at any clinic visit.
The current problem: equity and accuracy. The best-known T1D GRS was created using genetic information from thousands of European volunteers. That made sense at the time—data were available and cost was lower—but it means the test “learned” patterns common in Europeans, not in East Asians. Genetic studies show that key risk markers in Europeans, such as the HLA-DR3 and DR4 haplotypes, are rare in East Asians, while East Asia has its own risk haplotypes that the European score does not capture. As a result, East Asian families who take the European test may receive misleading results.
Real-world impact. Clinicians in Japan, Korea, and China report that many adults first labeled as type 2 diabetes later test antibody-positive and are re-classified as type 1. These patients often face years of sub-optimal treatment. Families with a relative who develops T1D are left without a clear genetic tool to assess risk in siblings and children. Scientists running prevention trials find that East Asian candidates are scarce, prolonging studies and delaying new treatments for everyone.
Scientific logic. By comparing the DNA of 1,000 East Asian adults with confirmed type 1 diabetes to 1,000 adults with type 2 diabetes, we can pinpoint the exact genetic markers that separate the two diseases in this ancestry. Weighting those markers yields a score that reflects true East-Asian genetic risk. Benchmarking against existing scores will quantify the improvement and confirm that the new score closes the current accuracy gap.
In essence, the rationale is simple yet powerful: early detection saves lives, but early detection must work for everyone. Building a Genetic Risk Score that finally serves East Asian people is the fastest, most cost-effective way to achieve that goal.
Description of Project
Type 1 diabetes (T1D) often looks as if it appears overnight, but the immune system can damage the pancreas for years before the first symptoms. Finding people in this silent phase saves lives: frequent checks stop dangerous diabetic ketoacidosis, and a new medicine, teplizumab, can delay full-blown diabetes for two years or more. Scientists already use a Genetic Risk Score (GRS)—a simple DNA test—to identify children at highest risk, yet the score was built almost entirely with European data. When it is used in East Asian families it misses many future patients, because the genetic patterns that drive T1D in Europeans differ from those in East Asians. The result is a serious equity gap: billions of Japanese, Korean, Chinese, and other East Asian people have no reliable path to early detection or timely treatment.
Our project solves this problem by creating the first T1D GRS tuned to East Asian DNA. Ten respected Japanese endocrinologists, including Dr Akira Shimada of the Japan Diabetes Society board, have joined forces. Together we will recruit 2000 adults across ten hospitals—about 1000 who have T1D and 1000 who have type 2 diabetes. Each volunteer will provide a saliva sample. A certified Japanese laboratory will read hundreds of thousands of genetic markers from each sample; powerful computer models will then search for the exact combination of markers that separates T1D from type 2 diabetes in East Asians. Public Korean, Chinese, and Taiwanese genetic datasets will help evaluate future, independent cross-border accuracy in the future.
We designed the study with privacy and fairness in mind. No names or personal details ever leave the hospital. DNA files are encrypted, analysed on a secure cloud for only a few months, and then permanently deleted. The original samples stay in Japan.
Success will deliver three practical wins. First, East Asian clinicians will finally have a low-cost tool—cheaper than many routine blood tests—to judge whether a patient is likely to develop T1D or whether an adult already diagnosed with diabetes actually has the autoimmune form. Second, families carrying high genetic risk can enroll in regular antibody screening and, when appropriate, receive teplizumab or emerging therapies before serious damage occurs. Third, researchers worldwide will gain access to a much-needed pool of East Asian volunteers for prevention trials, speeding the development of next-generation treatments.
Long term, the score we build here can be paired with newborn heel-prick DNA tests or national health-check programs to create a population-scale T1D genetic screening service in Japan. The same approach can then be adapted for other under-represented groups, moving global diabetes care toward a future where ancestry no longer dictates access to life-saving prevention. By transforming hidden genetic information into clear, actionable knowledge, our project gives every East Asian child and adult a fairer chance to stay one step ahead of type 1 diabetes.
Finally, this project shows how global teamwork can close equity gaps in precision medicine. Breakthrough T1D support will fund data aggregation, secure analysis, and transparent reporting. We will develop the East-Asian GRS, encouraging outside validation and rapid clinical use. Each East Asian child kept out of intensive care, each adult spared a misdiagnosis, will prove that impact investment can turn genetic discovery into longer, healthier lives.
Anticipated Outcome
When this project is complete, doctors, families, and researchers will gain a practical tool that has never existed before: a Genetic Risk Score calibrated to East Asian DNA. Here is what we expect to happen—step by step—once the score is in hand.
1. Reliable early-warning test for clinics.
Family physicians and diabetes specialists across Japan and other East Asian countries will be able to order a simple saliva-based test for patients who have a family history of T1D or unusual blood-sugar swings. Laboratories will run the new GRS algorithm and report a number that clearly falls into low or high risk. Because the algorithm is designed for East Asian genetics, its predictions will be as accurate as the best European scores are for European families. This will reduce misdiagnosis and ensure that high-risk individuals receive the right follow-up tests.
2. Earlier, safer use of preventive therapy.
Patients identified as high risk will enter regular autoantibody monitoring. If antibodies appear, doctors can offer teplizumab or future immunotherapies at precisely the stage where such treatments work best—before the pancreas is severely damaged. We anticipate a measurable drop in emergency ketoacidosis at first diagnosis, mirroring European screening programs that have already cut those dangerous admissions by more than half.
3. Faster recruitment for clinical trials.
Pharmaceutical companies and university researchers often struggle to enroll East Asian participants in trials aimed at delaying or preventing T1D. With a validated GRS, study teams can quickly find eligible volunteers, speeding up trials and making sure new drugs are tested in diverse populations. This benefits everyone by revealing whether treatments work equally well across ancestries.
4. Blueprint for other ancestry models.
Publishing the algorithm and its supporting data means researchers in South Asia, Africa, and Latin America can replicate the process. Within a decade, we envision a world where every major ancestry group has an accurate T1D genetic risk tool, making early detection truly global.
5. Economic benefits.
Preventing just one case of emergency diabetic ketoacidosis saves thousands of dollars in hospital costs. Delaying full-blown T1D by two years with teplizumab reduces insulin expenses and complications.
In summary, the anticipated outcome is more than a research paper. It is a ready-to-use, equity-focused screening tool that will transform how type 1 diabetes is detected, prevented, and studied in East Asia and beyond.
Relevance to T1D
Type 1 diabetes is an autoimmune disorder that strikes without warning, often in childhood, and lasts a lifetime. Although insulin therapy keeps people alive, daily management is demanding and long-term complications remain a threat. Preventing or even delaying the disease is therefore one of the most urgent challenges in modern medicine. Our project is tightly aligned with that mission, and here is why.
1. Closing an equity gap in early detection.
Current Genetic Risk Scores, used in Europe and North America, miss a substantial portion of East Asian individuals who will develop T1D. That means children in Japan or Korea may progress to full diabetes before anyone realizes the danger, arriving at hospital in crisis. By tailoring the score to East Asian genetics, we ensure that early-warning technology benefits everyone, not just those of European descent.
2. Enabling timely preventive therapy.
Teplizumab is the first drug proven to delay the onset of T1D, and more agents are in the pipeline. These treatments are effective only when given before the pancreas fails. An East-Asian GRS will flag high-risk individuals years earlier, creating a window for intervention and giving families precious time to prepare and adjust.
3. Improving diagnostic accuracy in adults.
Adults in East Asia are often labelled as type 2 diabetes even when their disease is autoimmune. Misclassification delays correct insulin therapy and can lead to rapid health decline. Our score will help clinicians distinguish between the two forms quickly, improving care from day one.
4. Fueling research diversity.
BreakthroughT1D and other organizations emphasize that therapies must work in all populations. Yet clinical trials continue to recruit mostly European-ancestry participants. By providing a precise way to identify East Asian candidates in the silent stage, our project will diversify trial cohorts, making results more reliable for the global community.
5. Supporting families with actionable information.
Families who have already faced T1D often worry about siblings or children. A personalized genetic risk number offers clarity and a structured monitoring plan, reducing uncertainty and empowering families to take preventive steps.
6. Creating a scalable model.
The project’s design—collect DNA, build an ancestry-specific score, validate locally, then roll out screening—can be reused for South Asian, African, or Latino communities. By proving the concept in East Asia, we blaze a trail for truly worldwide early detection.
7. Aligning with public-health goals.
Many East Asian countries, including Japan, run nationwide health-check programs. Adding a low-cost genetic test to existing infrastructure is practical and policy-friendly. The long-term aim is to integrate our score into routine pediatric or occupational health screenings, scaling up early detection at marginal extra cost.
8. Delivering economic value.
Early detection reduces emergency admissions and enables preventive therapy, both of which lower healthcare costs. Health-economic models suggest substantial savings over a patient’s lifetime when ketoacidosis is avoided and insulin dependence is delayed. Thus, investing in an East-Asian GRS is not only medically wise but fiscally responsible.
9. Advancing scientific knowledge.
Mapping the genetic architecture of T1D in East Asians may reveal new biological pathways, offering fresh targets for drug development that could benefit everyone with the disease.
Taken together, these points show that our project is highly relevant to the entire spectrum of type 1 diabetes efforts—from basic discovery, to clinical care, to public health. By ensuring that early detection and preventive therapy reach East Asian populations, we bring the global T1D community one step closer to a future where nobody is caught off guard by this challenging disease.